Multiagonists of the “incretin axis” as a promising tool for managing cardiometabolic risk in visceral obesity
Currently, the world experiences an increase in obesity prevalence, resulting in an increase in the incidence of diseases in which it is one of the leading factors, primarily type 2 diabetes and cardiovascular disease. This limits the effectiveness of preventive measures and determines the need to i...
Saved in:
| Main Authors: | M. A. Druzhilov, T. Yu. Kuznetsova, G. A. Chumakova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2022-05-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/4755 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Promising areas of pharmacotherapy for obesity
by: M. A. Druzhilov, et al.
Published: (2021-04-01) -
The associations of incretin hormone concentration with gestational diabetes mellitus
by: Tatiana V. Saprina, et al.
Published: (2016-05-01) -
PREDICTIVE SIGNIFICANCE OF ARTERIAL STIFFNESS PARAMETERS IN EVALUATION OF CARDIOMETABOLIC RISK IN OBESITY PATIENTS
by: O. Yu. Druzhilova, et al.
Published: (2018-06-01) -
Incretin hormone agonists as promising antiobesity drugs - review of literature
by: Aleksandra Grzegorczyk, et al.
Published: (2025-01-01) -
Incretins today: multiple effects and therapeutic potential
by: Oksana V. Tsygankova, et al.
Published: (2019-03-01)